Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese Adults Using Metabolomics Approach

March 23, 2022 updated by: Hasmiza Halib, Universiti Putra Malaysia

Effects of Flavanol-rich Dark Chocolate Consumption on Metabolic Profiles Among Obese

Obesity has become a global issue due to its alarming high and increasing prevalence worldwide and the roles it plays in occurrence of many chronic diseases. In addition, obesity is characterized as a state of chronic, low-grade inflammation and is associated with an abnormal inflammatory response, low antioxidant capacity and reduced insulin sensitivity which lead to the generation of inflammation, oxidative stress and insulin resistance.

As in Malaysia, study by National Health and Morbidity Survey Malaysia (NHMS) in 2011 and 2015 showed a continuing increase of the problem. In response to the rise of obesity prevalence, various efforts and strategies have been implemented in the past decade to combat this problem. The use of natural products as therapeutic agents in preventing metabolic disease has becoming popular. Cocoa and its products is a largely consumed food in the world. It has a very rich sources of phenolic compound. Several in vitro and in vivo studies have shown that polyphenols, with antioxidant, anti-inflammatory and anti-obesity properties, can boost energy expenditure and thermogenesis, lessen oxidative stress and inflammation while supporting weight loss management. Furthermore, the contribution of human studies especially among obese relatively limited.

The popularity of chocolate and/or cocoa and its frequent consumption made it the target of many research studies, due to its favourable effects, and to the significant role it may exert on improving the obesity condition. Therefore, this study aims to investigate the effects of flavanol-rich dark chocolate consumption on metabolic profiles of obese adults using metabolomic approach.

Study Overview

Detailed Description

Overnutrition and sedentary lifestyle are the leading factors associated with the development of obesity. Obese adults usually are advised to make lifestyle modifications which include dietary restriction and physical activity recommendation. In addition, dietary supplements and medication such as anti-hypertensive, lipid lowering drugs are used to achieved targeted body weight of obese adult. Therefore, the confounding factors in this study namely dietary intake, physical activity, medication, supplements were controlled throughout the study. These factors including smoking were also controlled as it will affect the metabolites.

Imbalance between energy intake and expenditure results in adipose tissue expansion due to excessive lipogenesis in adipose tissues. Generally, it is well accepted that adipose tissue expansion in an obese state is accompanied by elevated inflammation. Oxidative stress and pro-inflammatory processes are strongly related. Increased abdominal adipose tissue accelerates the production of pro-inflammatory cytokines which promote increased generation of ROS, both inflammation and oxidative stress play a significant role in the development of insulin resistant thus further are associated with the degree of metabolic dysfunction.

It was hypothesized that cocoa flavanol with the properties of anti-inflammation, anti-oxidative and antiobesity properties may reduce the oxidative stress and inflammation, subsequently reduce the insulin resistance and thus improved the outcome measurements in obese adult. In order to measures the altered metabolite in the urine and blood serum following cocoa rich flavanol consumption in dark chocolate in obese adult, a metabolomics based approach is used in this study.

This study is a randomized, open-labelled, parallel controlled trial where the intervention group will receive 20 grams of dark chocolate, daily for 12 weeks while the control group will receive 20 grams of white chocolate daily for 12 weeks. Measurement will be taken including sociodemographic, anthropometric measurement, diet and physical activity questionnaire, blood and urine samples at baseline and 12 weeks of intervention. Obese male adult aged 18-45 years old will be recruited

Study Type

Interventional

Enrollment (Anticipated)

74

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Selangor
      • Seri Kembangan, Selangor, Malaysia, 43400
        • Recruiting
        • Universiti Putra Malaysia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Malaysian
  • Obese BMI ≥ 25.0 kg/m2
  • Not on any drug or herbal preparation, antioxidative or any drugs or dietary supplement.
  • Do not have any chronic diseases
  • Do not have allergy to cocoa
  • Age 18-45 years old.

Exclusion Criteria:

  • Non-Malaysian
  • BMI < 25.0 kg/m2
  • Smokers and alcohol drinkers
  • Participants with cardiovascular diseases, hypertension or diabetes
  • Participants taking medications that affect insulin, glucose, lipid or blood pressure levels
  • Participants taking any dietary supplements
  • Have allergy towards cocoa beverages
  • Participants who are currently involved in a weight management program

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: cocoa polyphenols
21 grams of dark chocolate (289 mg polyphenols)
subjects will be given 21 grams of dark chocolate providing 289 mg of polyphenols per day for 12 weeks.
Placebo Comparator: polyphenols free
21 grams of white chocolate (0 mg polyphenols)
subjects will be given 21 grams of white chocolate (0 mg polyohenols) per day for 12 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in insulin resistance at 12 week
Time Frame: baseline and 8 weeks
Insulin resistance will be determined HOMA-IR and calculated as HOMA-IR = fasting serum x fasting blood glucose/22.5.
baseline and 8 weeks
change in insulin sensitivity at 8 weeks
Time Frame: baseline and 8 weeks
To assess insulin sensitivity, Quantitative Insulin Sensitivity Check Index (QUICKI) will be used and cutt off point of less than 0.33 indicates reduced insulin sensitivity
baseline and 8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in body weight at 8 weeks
Time Frame: baseline and 8 weeks
Body weight will be measured in kilograms using SECA electronic scale model 703.
baseline and 8 weeks
change in waist circumference at 8 weeks
Time Frame: baseline and 8 weeks
Waist circumference will be assessed at the midpoint between the lowest rib andd the iliac crest using a non-stretchable tape measure. The measurement will be conducted twice to the nearest 0.1cm. The cutoff points for waist ciircumference by WHO expert committee on obesity in Asian and Pacific populations are >90 cm for men and >80cm fro women.
baseline and 8 weeks
change in lipid profiles (TG, HDL-c, LDL-c, TC) at 8 weeks
Time Frame: baseline and 8 weeks
Lipid profiles (TG, Cholesterol, LDL-c, and HDL-c) will be determined using commercially available kits using Architect ci8200 analyzer
baseline and 8 weeks
change in inflammatory markers (C-reactive protein ) at 8 week
Time Frame: baseline and 8 weeks
C-reactive protein will be measured using kits of human inflammatory cytokines by Enzyme Linked Inmuno Sorbent Assay from blood serum and will be expressed as mg/L.
baseline and 8 weeks
change in oxidative stress markers (oxidized LDL) at 8 week
Time Frame: baseline and 8 weeks
Levels of LDL-ox in plasma will be analysed at the beginning and the end (8 weeks) and will be expressed as mg/L.
baseline and 8 weeks
changes in metabolomics profiles following flavanol-rich dark chocolate consumption at 8 week
Time Frame: baseline and 8 weeks
Metabolomic analysis of the plasma sample will be performed using 1H-NMR platform
baseline and 8 weeks
changes in gut microbiome status following flavanol-rich dark chocolate consumption at 8 week
Time Frame: baseline and 8 weeks
metagenomic analysis of fecal samples will be analysed at the beginning and end (8 weeks)
baseline and 8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Amin Ismail, PhD, Universiti Putra Malaysia

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 23, 2022

Primary Completion (Anticipated)

June 23, 2022

Study Completion (Anticipated)

September 1, 2022

Study Registration Dates

First Submitted

April 7, 2020

First Submitted That Met QC Criteria

April 12, 2020

First Posted (Actual)

April 15, 2020

Study Record Updates

Last Update Posted (Actual)

April 4, 2022

Last Update Submitted That Met QC Criteria

March 23, 2022

Last Verified

March 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • NMRR-19-3092-51617.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Dark chocolate (20 grams) per day providing 508 mg of polyphenols

Subscribe